HUMA Humacyte Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: HUMA

Price (delayed)

$3.59

Market cap

$427.51M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.07

Enterprise value

$404.57M

Highlights
The gross profit has dropped by 100% year-on-year
The revenue has shrunk by 100% YoY
Sector: Healthcare
Industry: Biotechnology
Peers: OCX OGEN OLMA OMER

Key stats

What are the main financial stats of HUMA
Market
Shares outstanding
119.08M
Market cap
$427.51M
Enterprise value
$404.57M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
27.45
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$104.18M
EBITDA
-$96.41M
Free cash flow
-$75.59M
Per share
EPS
-$1.07
Free cash flow per share
-$0.73
Book value per share
$0.13
Revenue per share
$0
TBVPS
$1.24
Balance sheet
Total assets
$128.22M
Total liabilities
$114.68M
Debt
$57.51M
Equity
$13.55M
Working capital
$64.84M
Liquidity
Debt to equity
4.25
Current ratio
4.52
Quick ratio
4.36
Net debt/EBITDA
0.24
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-70.5%
Return on equity
-228.9%
Return on invested capital
-116.8%
Return on capital employed
-94.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HUMA stock price

How has the Humacyte stock price performed over time
Intraday
15.06%
1 week
18.87%
1 month
2.28%
1 year
7.49%
YTD
26.41%
QTD
15.43%

Financial performance

How have Humacyte's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$100.05M
Net income
-$110.78M
Gross margin
N/A
Net margin
N/A
The gross profit has dropped by 100% year-on-year
The revenue has shrunk by 100% YoY
HUMA's net income is down by 24% since the previous quarter
HUMA's operating income is down by 18% year-on-year and by 6% since the previous quarter

Growth

What is Humacyte's growth rate over time

Valuation

What is Humacyte stock price valuation
P/E
N/A
P/B
27.45
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
HUMA's EPS is down by 23% since the previous quarter
HUMA's price to book (P/B) is 183% higher than its last 4 quarters average of 9.7
The company's equity has shrunk by 88% YoY and by 63% QoQ
The revenue has shrunk by 100% YoY

Efficiency

How efficient is Humacyte business performance
HUMA's ROE has dropped by 90% since the previous quarter
Humacyte's return on assets has decreased by 39% QoQ
HUMA's return on invested capital is down by 25% since the previous quarter

Dividends

What is HUMA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HUMA.

Financial health

How did Humacyte financials performed over time
HUMA's total assets is 12% higher than its total liabilities
The quick ratio is down by 44% YoY and by 34% QoQ
HUMA's current ratio is down by 43% YoY and by 33% from the previous quarter
The debt to equity has soared by 178% since the previous quarter
The company's equity has shrunk by 88% YoY and by 63% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.